Stockscreener 앱 받기
3.58
5.79%
-0.22
시간 외 거래:
3.55
-0.03
-0.84%
전일 마감가:
$3.80
열려 있는:
$3.66
하루 거래량:
977.50K
Relative Volume:
1.85
시가총액:
$1.12B
수익:
$548.10M
순이익/손실:
$69.50M
주가수익비율:
15.54
EPS:
0.2303
순현금흐름:
$-137.90M
1주 성능:
+1.13%
1개월 성능:
-17.13%
6개월 성능:
-54.57%
1년 성능:
-68.43%
1일 변동 폭
$3.4202
$3.68
1주일 범위
$3.4202
$3.88
52주 변동 폭
$3.4202
$11.85
Alvotech Stock (ALVO) Company Profile
Compare ALVO vs TAK, ZTS, HLN, TEVA, UTHR
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALVO
Alvotech
|
3.58 | 1.18B | 548.10M | 69.50M | -137.90M | 0.2303 |
|
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 56.96B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
115.99 | 49.54B | 9.47B | 2.67B | 2.28B | 6.0218 |
|
HLN
Haleon Plc Adr
|
10.23 | 45.90B | 14.54B | 2.22B | 2.58B | 0.4871 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
29.44 | 34.48B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
527.00 | 23.24B | 3.18B | 1.33B | 1.04B | 27.90 |
Alvotech Stock (ALVO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Barclays | Underweight |
| 2025-11-04 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-10-14 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-09-23 | 업그레이드 | Deutsche Bank | Hold → Buy |
| 2025-02-14 | 개시 | UBS | Buy |
| 2024-01-29 | 업그레이드 | Barclays | Equal Weight → Overweight |
| 2023-10-20 | 업그레이드 | Citigroup | Sell → Neutral |
| 2023-09-21 | 개시 | Barclays | Equal Weight |
| 2022-09-07 | 개시 | Morgan Stanley | Equal-Weight |
| 2022-09-06 | 다운그레이드 | Citigroup | Buy → Sell |
| 2022-07-26 | 개시 | Citigroup | Buy |
모두보기
Alvotech 주식(ALVO)의 최신 뉴스
Alvotech Q4 2025 slides: 21% revenue growth amid FDA hurdles - Investing.com
ALVO: 2025 revenue rose 21% to $593M; 2026 guidance set at $650–$700M with strong pipeline momentum - TradingView
Alvotech Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Alvotech Q4 2025 Surpasses Earnings Forecast - Investing.com
Alvotech Posts Strong 2025 Growth, Adds Approvals and New CEO as Biosimilar Pipeline Expands - TipRanks
Alvotech (NASDAQ: ALVO) turns profit as 2025 revenue rises 21% and sets 2026 growth targets - Stock Titan
Alvotech earnings beat by $0.11, revenue topped estimates - Investing.com India
Alvotech Q4 Revenue Increases; 2026 Revenue Guidance Issued - marketscreener.com
Alvotech SA reports results for the quarter ended December 31Earnings Summary - TradingView
Alvotech (NASDAQ:ALVO) Reports Q4 Revenue Beat but Significant EPS Miss, Stock Falls on Weak Guidance - ChartMill
ALVOTECH ($ALVO) Releases Q4 2025 Earnings - Quiver Quantitative
Alvotech Reports Strong Q4 2025 Financial Results and Provides Business Update on Biosimilar Developments - Quiver Quantitative
Alvotech Q4 2025 and Full Year 2025 Financial Results - Caledonian Record
Alvotech expects four U.S. biosimilar approvals by late 2026 - Stock Titan
Alvotech’s fourth quarter results need to support the bearish outlook in order to shift the prevailing story - Bitget
Earnings Scheduled For March 18, 2026 - Benzinga
Alvotech, Teva reach settlement and license agreement with Regeneron for AVT06 - MSN
Alvotech's Guidance Hike Sets Higher Bar for 2026 Growth Execution - Bitget
Alvotech's Q4 Report: Regulatory Concerns for AVT05 Diminish Impact of Revenue Outperformance - Bitget
Alvotech (ALVO) Q4 2025 Earnings Report Preview: What To Expect - GuruFocus
(ALVO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Alvotech stock hits 52-week low at 3.65 USD - Investing.com Nigeria
Alvotech Stock (ISIN: LU2557688560) Faces Headwinds as Short Interest Climbs 18.4% - AD HOC NEWS
Alvotech SA expected to post a loss of 4 cents a shareEarnings Preview - TradingView
Alvotech (NASDAQ:ALVO) Short Interest Up 18.4% in February - MarketBeat
Alvotech (NASDAQ:ALVO) Emerges In Nasdaq Composite Biotech Discussions - Kalkine Media
Quant snapshot: Micron, Babcock & Wilcox lead strong buys as Fold Holdings, Alvotech lag - MSN
Alvotech, Advanz Pharma get EU nod for Eylea biosimilar - MSN
Earnings Preview: Alvotech to Report Financial Results Post-market on March 18 - 富途牛牛
Alvotech (NASDAQ: ALVO) investor group reports 33.3% beneficial stake - Stock Titan
Alvotech (NASDAQ:ALVO) Hits New 52-Week LowTime to Sell? - MarketBeat
Alvotech files automatic mixed securities shelf - MSN
Alvotech (ALVO) Projected to Post Earnings on Wednesday - MarketBeat
Alvotech (ALVO) Announces Acquisition of Ivers-Lee Group - MSN
Will Alvotech stock attract ESG investorsCPI Data & AI Enhanced Trading Signals - Naître et grandir
Alvotech Stock Plummets to New 52-Week Low of $3.65 - Markets Mojo
ALVO Earnings History & Surprises | EPS & Revenue Results | ALVOTECH SA (NASDAQ:ALVO) - ChartMill
Alvotech to Release Fourth Quarter and Full Year 2025 Financial Results - geneonline.com
Alvotech to Announce Q4 and Full Year 2025 Financial Results on March 18, 2026 - Quiver Quantitative
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Alvotech schedules March 18 earnings, March 19 investor call - Stock Titan
Alvotech (ALVO) Stock Analysis: Exploring A Potential 375% Upside In The Biosimilar Market - DirectorsTalk Interviews
Alvotech : Managers' transactionsALVOTECH - marketscreener.com
Alvotech stock hits 52-week low at 3.89 USD By Investing.com - Investing.com South Africa
Alvotech’s Biosimilar Bet: Why Wall Street Is Suddenly Watching - AD HOC NEWS
Alvotech (ALVOW) Competitors - Meyka
Alvotech (NASDAQ:ALVO) Sets New 12-Month LowShould You Sell? - MarketBeat
Alvotech stock hits 52-week low at 3.89 USD - Investing.com
Alvotech (NASDAQ:ALVO) Given Average Recommendation of "Reduce" by Analysts - MarketBeat
Alvotech Discloses Intra-Group Transfer of 2.7 Million Shares Within Aztiq Group - TipRanks
Alvotech (NASDAQ: ALVO) discloses 2.7M-share intra-group transfer at $4.74 - Stock Titan
Alvotech (ALVO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.02%
0.77%
자본화:
|
볼륨(24시간):